NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX)

 
CPRX Technical Analysis
3
As on 2nd Dec 2025 CPRX STOCK Price closed @ 22.62 and we RECOMMEND Buy for LONG-TERM with Stoploss of 22.02 & Buy for SHORT-TERM with Stoploss of 22.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

CPRXSTOCK Price

Open 22.79 Change Price %
High 22.93 1 Day -0.07 -0.31
Low 22.42 1 Week -0.15 -0.66
Close 22.62 1 Month 1.61 7.66
Volume 1034571 1 Year 0.55 2.49
52 Week High 26.31 | 52 Week Low 19.13
 
NASDAQ USA Most Active Stocks
LPTX 2.05 365.91%
AMRS 0.14 100.00%
WBA 11.98 0.50%
BYND 1.29 -3.73%
NVDA 181.46 0.86%
INTC 43.47 8.65%
PLUG 2.11 9.90%
LMDX 0.02 0.00%
AKTS 0.04 0.00%
BITF 3.10 -5.49%
 
NASDAQ USA Top Gainers Stocks
MRIN 3450.00 383233.34%
MRIN 3450.00 383233.34%
CHEK 183.00 11266.46%
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
TLRY 7.71 888.46%
TLRY 7.71 888.46%
CTXRW 0.14 600.00%
LPTX 2.05 365.91%
 
NASDAQ USA Top Losers Stocks
FPAY 0.01 -94.74%
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
SWSSU 1.06 -89.40%
ORGS 0.15 -83.52%
OTRK 0.07 -78.79%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
OPI 0.06 -70.00%
OPI 0.06 -70.00%
 
 
CPRX
Daily Charts
CPRX
Intraday Charts
Whats New @
Bazaartrend
CPRX
Free Analysis
 
CPRX Important Levels Intraday
RESISTANCE23.60
RESISTANCE23.29
RESISTANCE23.09
RESISTANCE22.90
SUPPORT22.34
SUPPORT22.15
SUPPORT21.95
SUPPORT21.64
 
CPRX Forecast December 2025
4th UP Forecast31.97
3rd UP Forecast28.97
2nd UP Forecast27.12
1st UP Forecast25.26
1st DOWN Forecast19.98
2nd DOWN Forecast18.12
3rd DOWN Forecast16.27
4th DOWN Forecast13.27
 
CPRX Weekly Forecast
4th UP Forecast24.62
3rd UP Forecast23.98
2nd UP Forecast23.58
1st UP Forecast23.19
1st DOWN Forecast22.05
2nd DOWN Forecast21.66
3rd DOWN Forecast21.26
4th DOWN Forecast20.62
 
CPRX Forecast2025
4th UP Forecast37.13
3rd UP Forecast32.48
2nd UP Forecast29.6
1st UP Forecast26.72
1st DOWN Forecast18.52
2nd DOWN Forecast15.64
3rd DOWN Forecast12.76
4th DOWN Forecast8.11
 
 
CPRX Other Details
Segment EQ
Market Capital 613333760.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
CPRX Address
CPRX
 
CPRX Latest News
 
Your Comments and Response on Catalyst Pharmaceuticals Inc
 
CPRX Business Profile
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Address: 355 Alhambra Circle, Coral Gables, FL, United States, 33134
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service